Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Better Buy: Pfizer Inc. (PFE) or Zoetis Inc (ZTS)?

Page 1 of 2

Pfizer Inc. (NYSE:PFE) recently spun off animal health firm Zoetis Inc (NYSE:ZTS) in the form of an IPO. Should you take a spin in the animal kingdom or stick with treating humans? Let’s take a look a closer look at their business models.

Research & development
Zoetis’ model relies on leveraging existing animal health products by adding new species or claims to existing drugs. It’s also focused on gaining approvals in new markets and on creating new combinations and reformulations. In other words, there’s not a lot of innovation going on.

Zoetis Inc (NYSE:ZTS)While it’s done its fair share of me-too drugs, Pfizer’s human drug development is more innovative. That comes at a higher cost, but should pay off down the line with higher-priced drugs.

Animal health is generally a cash payer market. The animal’s owners pay distributors directly for the drugs. Pfizer, on the other hand, has to deal with insurers trying to negotiate lower prices and jump through hoops to get its drugs covered.

Zoetis clearly has the advantage here, especially as health-care reform highlights drug pricing as a contentious issue.

Zoetis is the largest provider of animal health products, but it does have competition from Merck & Co., Inc. (NYSE:MRK)‘s animal health business, Sanofi SA (ADR) (NYSE:SNY)‘s Merial, Bayer, Boehringer Ingelheim, and Eli Lilly & Co.(NYSE:LLY). Interestingly, the companies seem to have found their own niches which has cut down on competition at the product level, allowing everyone to survive.

The lack of competition in individual products means antitrust issues come into play if companies try to join forces to top Zoetis like Merck & Co., Inc.(NYSE:MRK) and Sanofi did a few years ago. Some human diseases have substantial competition, but the markets are so much larger that even a small piece of a market can produce sales of hundreds of million dollars. Both Zoetis and Pfizer are big players in their respective fields and aren’t going to get pushed around.

Like human medicines, drugs for animals are covered by patents. Unlike humans, though, when patents expire, it isn’t as big of a deal for a couple of reasons.

First, there’s no Lipitor of the animal drug world. Zoetis sells hundreds of products. In 2011, its top-selling product line, the ceftiofur line, contributed less than 8% of revenue. Losing patent protection on one drug isn’t crucial. Second, because of the smaller market size, there’s less incentive for generics to enter the market when a medication goes off patent. Finally, brand loyalty can keep customers around even after the drug does go off patent. There’s no pharmacist following insurer’s instructions to automatically switch patients to a generic.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!